Competition for anti-VEGF market heats up with release of additional Phase III data from Novartis on new wet AMD treatment
Novartis AG (NYSE:NVS; SIX:NOVN) has announced additional data form their Phase III HAWK and HARRIER trials of brolucizumab (RTH258) for the treatment of wet AMD. The most recent data shows an improved advantage for the Novartis drug over the competing Eylea treatment from Regeneron Pharmaceuticals Inc. The Novartis sponsored research reported that 6 mg brolucizumab […]Read full story
Stem cell therapy clinical trial demonstrates safety and potential efficacy in small numbers of patients
Positive preliminary findings have been reported from Phase I and Phase 2 clinical research using retinal pigment epithelial (RPE) cells derived from embryonic stem cells. The studies have indicated that patients with AMD and Stargardt’s may have early signs of vision gain following the stem cell treatment. Dr. Eyal Banin, from Hadassah-Hebrew University Medical Centre, […]Read full story
Macular atrophy development in patients treated with anti-VEGFs show a clear association with subretinal drusenoid deposits.
Researchers based at New York University School of Medicine have published research confirming an association between subretinal drusenoid deposits (SDD) and macular atrophy (MA) in neovascular AMD patients treated with anti-VEGF medication. The research, conducted on 71 patients with a diagnosis of neovascularisation, but not previously treated with anti-VEGF therapy, showed that SDD was a […]Read full story